Sugi Predict

Sugi Predict / Compounds / SCHEMBL5538341

SCHEMBL5538341

SCHEMBL5538341

CC(C)(C)OC(=O)N1CCC(Oc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.63

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 7/20 0.63
▸ LIPE Q05469 1/20 0.56
▸ MAPT P10636 1/20 0.54
▸ EPHX2 P34913 1/20 0.54
▸ USP30 Q70CQ3 1/20 0.51
▸ CHEK2 O96017 1/20 0.51
▸ STS P08842 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ TEAD1 P28347 1/20 0.50
▸ ADRB2 P07550 1/20 0.50
▸ MMP2 P08253 1/20 0.49
▸ MMP13 P45452 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23632967 0.93 USP30 (0.57) GPR119LIPEMAPTEPHX2USP30
SCHEMBL23632146 0.93 USP30 (0.57) GPR119LIPEMAPTEPHX2USP30
SCHEMBL3077366 0.93 USP30 (0.57) GPR119LIPEMAPTEPHX2USP30
SCHEMBL2951108 0.87 GPR119 (0.63) GPR119LIPEEPHX2USP30CHEK2
SCHEMBL21723304 0.87 USP30 (0.53) GPR119LIPEMAPTEPHX2USP30
SCHEMBL3073527 0.87 GPR119 (0.65) GPR119USP30CHEK2ALDH1A1MMP13
SCHEMBL75960 0.86 GPR119 (0.62) GPR119LIPEEPHX2USP30CHEK2
SCHEMBL13974435 0.86 GPR119 (0.56) GPR119CHEK2
SCHEMBL6036543 0.85 EPHX2 (0.57) GPR119EPHX2USP30STS
SCHEMBL29280843 0.85 CHEK2 (0.54) GPR119LIPEMAPTUSP30CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12268687-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-08 — — US disclosed
US-20250034124-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2025-01-30 — — US disclosed
US-12098146-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-09-24 — — US disclosed
US-11918575-B2 PZA and cytochrome Bc1 inhibitor combination treatment Janssen Sciences Ireland Unlimited Company (IE) 2024-03-05 — — US disclosed
US-20230116101-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS, INC. 2023-04-13 — — US disclosed
US-20230014173-A1 Antibacterial Compounds JANSSEN SCIENCES IRELAND UC (IE) 2023-01-19 — — US disclosed
WO-2022130352-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2022-06-23 — — WO disclosed
US-11224596-B2 PZA and cytochrome bc1 inhibitor combination treatment Janssen Sciences Ireland Unlimited Company (IE) 2022-01-18 — — US disclosed
CN-113906019-A Compound and use thereof 优曼尼蒂治疗公司 2022-01-07 — — CN disclosed
EP-3914593-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2021-12-01 — — EP disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 — — EP disclosed
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2005-03-03 — — US disclosed
US-6800646-B1 Sulfamato hydroxamic acid metalloprotease inhibitor PHARMACIA CORPORATION 2004-10-05 — — US disclosed
US-20040192733-A1 Hydroxamic acid derivatives UCB PHARMA S.A. (BE) 2004-09-30 — — US disclosed
EP-1414812-A1 HYDROXAMIC ACID DERIVATIVES Celltech R & D Limited (GB) 2004-05-06 — — EP disclosed
WO-2003014101-A1 HYDROXAMIC ACID DERIVATIVES CELLTECH R & D LIMITED (GB) 2003-02-20 — — WO disclosed
US-6492367-B1 Sulfamato hydroxamic acid metalloprotease inhibitor G. D. SEARLE & COMPANY 2002-12-10 — — US disclosed
US-6448250-B1 INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 G. D. SEARLE & COMPANY 2002-09-10 — — US disclosed
EP-1157021-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2001-11-28 — — EP disclosed
WO-2000046221-A1 SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR G.D. SEARLE & CO. (US) 2000-08-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11224596-B2 PZA and cytochrome bc1 inhibitor combination treatment CYC1, MT-ND1, MT-CO1 GPR119 3620/4885LIPE 4329/4885MAPT 4175/4885
US-20250034124-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GPR119 3998/4885LIPE 4826/4885MAPT 101/4885
US-12268687-B2 Compounds and uses thereof NLN, BDNF, NQO1 GPR119 3998/4885LIPE 4826/4885MAPT 101/4885
US-20050049280-A1 Sulfamato hydroxamic acid metalloprotease inhibitor MMP14, MMP12, MMP17 GPR119 4618/4885LIPE 2265/4885MAPT 3934/4885
US-20230014173-A1 Antibacterial Compounds FDPS, SQOR, NDUFS3 GPR119 4679/4885LIPE 3561/4885MAPT 1437/4885
US-20230116101-A1 COMPOUNDS AND USES THEREOF NLN, BDNF, NQO1 GPR119 3998/4885LIPE 4826/4885MAPT 101/4885
US-11918575-B2 PZA and cytochrome Bc1 inhibitor combination treatment CYC1, MT-ND1, MT-CO1 GPR119 3620/4885LIPE 4329/4885MAPT 4175/4885
US-20040192733-A1 Hydroxamic acid derivatives MMP1, MMP3, MMP13 GPR119 3316/4885LIPE 2356/4885MAPT 4451/4885
US-12098146-B2 Compounds and uses thereof NLN, BDNF, NQO1 GPR119 3998/4885LIPE 4826/4885MAPT 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.